Nuvation Bio INC. (NUVB) — SEC Filings

Overview

Nuvation Bio INC. (NUVB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 21, 2026: Nuvation Bio Inc. filed a Definitive Additional Materials (DEFA14A) on April 21, 2026. The filing, with SEC Accession Number 0001140361-26-015827, contains 30966 documents. The company's mailing and business address is 1500 Broadway, Suite 1401, New York, NY 10036.

Sentiment Summary

Across 40 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 36 neutral, 1 mixed. The dominant filing sentiment for Nuvation Bio INC. is neutral.

Filing Type Overview

Nuvation Bio INC. (NUVB) has filed 1 DEFA14A, 1 ARS, 20 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13G/A, 2 SC 13D/A, 1 SC 13D, 1 8-K/A, 1 10-K/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (40)

• Nuvation Bio Files Definitive Additional Materials — DEFA14A · Apr 21, 2026 Risk: low
  Nuvation Bio Inc. filed a Definitive Additional Materials (DEFA14A) on April 21, 2026. The filing, with SEC Accession Number 0001140361-26-015827, contains 3096
• Nuvation Bio Files 2025 Annual Report — ARS · Apr 10, 2026 Risk: low
  Nuvation Bio Inc. filed an Annual Report to Security Holders (ARS) on April 10, 2026, for the period ending December 31, 2025. The company, headquartered in New
• 8-K Filing — 8-K · Nov 26, 2025
• Nuvation Bio Inc. Files 8-K with Financial Updates — 8-K · Nov 17, 2025 Risk: low
  Nuvation Bio Inc. filed an 8-K on November 17, 2025, reporting on various events and financial statements. The company, formerly Panacea Acquisition Corp. until
• Nuvation Bio's Q3 Loss Widens, Revenue Jumps on Product Launch — 10-Q · Nov 3, 2025 Risk: high
  Nuvation Bio Inc. reported a net loss of $55.79 million for the three months ended September 30, 2025, an increase from a net loss of $41.21 million in the same
• Nuvation Bio Files 8-K on Operations and Financials — 8-K · Aug 7, 2025 Risk: low
  Nuvation Bio Inc. filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements
• Nuvation Bio's Q2 Loss Widens Amid Rising R&D Spend — 10-Q · Aug 7, 2025 Risk: high
  Nuvation Bio Inc. reported a net loss of $58.3 million for the three months ended June 30, 2025, a significant increase from the $48.9 million net loss in the p
• Nuvation Bio Inc. Files 8-K — 8-K · Jun 11, 2025 Risk: low
  Nuvation Bio Inc. filed an 8-K on June 11, 2025, reporting on other events and financial statements. The company, formerly Panacea Acquisition Corp., is incorpo
• Nuvation Bio Inc. Files 8-K on Shareholder Vote Matters — 8-K · May 23, 2025 Risk: low
  Nuvation Bio Inc. filed an 8-K on May 23, 2025, reporting on a submission of matters to a vote of security holders that occurred on May 21, 2025. The company, f
• Nuvation Bio Files 8-K on Financials — 8-K · May 7, 2025 Risk: low
  Nuvation Bio Inc. filed an 8-K on May 7, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and
• Nuvation Bio Files Q1 2025 10-Q Report — 10-Q · May 7, 2025 Risk: medium
  Nuvation Bio Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly Panacea Acquisition Corp, is focused on pharmaceutical
• Nuvation Bio Files Definitive Proxy Statement — DEF 14A · Apr 8, 2025 Risk: low
  Nuvation Bio Inc. filed its definitive proxy statement (DEF 14A) on April 8, 2025, for its annual meeting on May 21, 2025. The company, formerly known as Panace
• Nuvation Bio Enters Material Definitive Agreement — 8-K · Mar 25, 2025 Risk: medium
  Nuvation Bio Inc. entered into a material definitive agreement on March 21, 2025. The company, formerly known as Panacea Acquisition Corp., is incorporated in D
• Nuvation Bio Files 8-K on Financials — 8-K · Mar 6, 2025 Risk: low
  Nuvation Bio Inc. filed an 8-K on March 6, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements a
• 10-K Filing — 10-K · Mar 6, 2025
• Nuvation Bio Inc. Enters Material Definitive Agreement — 8-K · Mar 5, 2025 Risk: medium
  On March 3, 2025, Nuvation Bio Inc. entered into a material definitive agreement. The company, formerly known as Panacea Acquisition Corp. until April 30, 2020,
• Nuvation Bio Inc. Enters Material Agreement, Incurs Financial Obligation — 8-K · Mar 4, 2025 Risk: medium
  On March 3, 2025, Nuvation Bio Inc. entered into a material definitive agreement and created a direct financial obligation. The company, formerly known as Panac
• Nuvation Bio Inc. Reports Officer and Director Changes — 8-K · Feb 12, 2025 Risk: medium
  Nuvation Bio Inc. filed an 8-K on February 12, 2025, reporting changes effective February 11, 2025. The filing pertains to the departure of directors or certain
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• Nuvation Bio Inc. Files 8-K on Financials — 8-K · Nov 6, 2024 Risk: low
  Nuvation Bio Inc. filed an 8-K on November 6, 2024, reporting on its results of operations and financial condition. The filing indicates the company's principal
• Nuvation Bio Files Q3 2024 10-Q — 10-Q · Nov 6, 2024 Risk: medium
  Nuvation Bio Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly Panacea Acquisition Corp., reported financial data for the thir
• Omega Fund V Amends Nuvation Bio Stake — SC 13D/A · Oct 18, 2024 Risk: medium
  Omega Fund V, L.P., along with Otello Stampacchia and Claudio Nessi, filed an amendment (No. 2) to their Schedule 13D on October 18, 2024, regarding their holdi
• Nuvation Bio Inc. Reports Director Changes and Compensation Updates — 8-K · Oct 7, 2024 Risk: medium
  Nuvation Bio Inc. announced on October 7, 2024, a change in its board of directors and executive compensation arrangements. The filing details the departure of
• Decheng Capital Discloses Nuvation Bio Stake — SC 13D · Sep 10, 2024 Risk: medium
  On September 10, 2024, Decheng Capital China Life Sciences USD Fund III, L.P. filed an SC 13D, reporting beneficial ownership of Nuvation Bio Inc. common stock.
• Nuvation Bio Inc. Files 8-K on Shareholder Votes and Events — 8-K · Sep 5, 2024 Risk: low
  Nuvation Bio Inc. filed an 8-K on September 5, 2024, reporting on matters submitted to a vote of security holders and other events that occurred on September 3,
• Nuvation Bio Files 8-K on Operations and Financials — 8-K · Aug 5, 2024 Risk: low
  Nuvation Bio Inc. filed an 8-K on August 5, 2024, reporting on its results of operations and financial condition. The filing indicates the company's incorporati
• Nuvation Bio Files Q2 2024 10-Q — 10-Q · Aug 5, 2024 Risk: medium
  Nuvation Bio Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial condition, including cash equivalents and marketable
• Nuvation Bio Files Proxy Statement for Annual Meeting — DEF 14A · Jul 30, 2024 Risk: low
  Nuvation Bio Inc. filed its definitive proxy statement (DEF 14A) on July 30, 2024, for its annual meeting on September 3, 2024. The filing details executive com
• Nuvation Bio Inc. Amends Filing with Financial Data — 8-K/A · Jun 20, 2024 Risk: low
  Nuvation Bio Inc. filed an 8-K/A on June 20, 2024, to amend a previous filing related to other events and financial statements. The filing includes financial da
• Nuvation Bio Inc. Files 8-K on Operations — 8-K · May 14, 2024 Risk: low
  Nuvation Bio Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition. The filing indicates the company's principal exe
• Nuvation Bio Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024 Risk:
  Nuvation Bio Inc. (NUVB) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Nuvation Bio Inc. filed a 10-Q report for the period ending March 31, 202
• Nuvation Bio Inc. Files 10-K/A Amendment No. 1 for Fiscal Year Ended December 31, 2023 — 10-K/A · Apr 26, 2024 Risk: low
  Nuvation Bio Inc. (NUVB) filed a Amended Annual Report (10-K/A) with the SEC on April 26, 2024. Nuvation Bio Inc. filed an amendment (10-K/A) to its annual repo
• Nuvation Bio Completes SPAC Merger, Raises $100M — 8-K · Apr 10, 2024 Risk: medium
  Nuvation Bio Inc. announced on April 9, 2024, the completion of its business combination with Anzu Special Acquisition Corp I. This transaction resulted in the
• David Hung Amends Nuvation Bio Stake — SC 13D/A · Mar 26, 2024 Risk: medium
  David Hung, M.D. has amended his Schedule 13D filing for Nuvation Bio Inc. on March 26, 2024. The filing indicates a change in beneficial ownership of the compa
• Nuvation Bio Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Mar 25, 2024 Risk: medium
  Nuvation Bio Inc. announced on March 24, 2024, that it entered into a Material Definitive Agreement. The company also disclosed unregistered sales of equity sec
• Nuvation Bio Files 8-K on Financials — 8-K · Feb 29, 2024 Risk: low
  Nuvation Bio Inc. filed an 8-K on February 29, 2024, reporting on its results of operations and financial condition. The filing includes financial statements an
• Nuvation Bio Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 29, 2024 Risk: medium
  Nuvation Bio Inc. (NUVB) filed a Annual Report (10-K) with the SEC on February 29, 2024. Nuvation Bio Inc. filed its annual report on Form 10-K for the fiscal y
• FMR LLC & Abigail Johnson Report 11.989% Stake in Nuvation Bio — SC 13G/A · Feb 9, 2024 Risk: low
  FMR LLC, a major investment firm, and its CEO, Abigail P. Johnson, have updated their ownership in Nuvation Bio Inc. (NUVB) Class A Common Stock. As of February
• BlackRock Discloses Passive Stake in Nuvation Bio (NUVB) — SC 13G · Jan 29, 2024
  BlackRock Inc., a major investment firm, filed an SC 13G on January 29, 2024, disclosing its ownership of Nuvation Bio Inc. (NUVB) common stock as of December 3
• Nuvation Bio Relocates HQ to New York City — 8-K · Jan 8, 2024
  Nuvation Bio Inc. filed an 8-K on January 8, 2024, to report a change in its principal executive offices from 357 Tehama Street, San Francisco, CA 94103 to 1500

Related Companies

NUVO · NUVA · NVBN · ANZU

Frequently Asked Questions